US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Stage

0.3754

0.0000

Volume:- -

Turnover:- -

Market Cap:10.85M

PE:-0.11

High:0.3754

Open:0.3754

Low:0.3754

Close:0.3754

Loading ...

Overview Company News Filings

Stage 6 Now Live: 3 Best Meme Coin Presales to Buy Now Feature Dogecoin, Pepe, and a Low-Cap Gem at $0.00001459

Missed Dogs? This Cat’s Stage 5 Is Ending—4453.17% ROI Still on the Table

Market Chatter: Nippon Steel President Says Talks With US Government Over US Steel Takeover at Final Stage

MT Newswires Live

Press Release: DSS, Inc. Reports Strong Q1 2025 Financial Performance, Setting the Stage for Strategic Growth

Instil Bio, ImmuneOnco Say Lung Cancer Drug `2510 Mid-Stage Trial Enrollment in China on Track for Q3

MT Newswires Live

Mind Medicine’s Strategic Advancements and Late-Stage Pipeline Progress Justify Buy Rating

Google I/O Conference Takes the Stage: Entering the 'AI Era,' Can Investor Confidence Rebound?

Zymeworks: Hold Rating Maintained Amid Financial Improvements and Early-Stage Growth Potential

Succinct is set to launch the Succinct Prover Network architecture and the PROVE token.

UBE Corporation Unveils ‘UBE Vision 2030 Transformation — 2nd Stage’

Astrazeneca's Asthma Therapy Shows Improvement Across Primary and Secondary Endpoints in Late-Stage Trial

MT Newswires Live

Warren Buffett Will Not Take Stage at Berkshire Hathaway’s (BRK.B) Future Annual Meetings

Warren Buffett Won't Take the Stage for Questions at Berkshire's Next Annual Meeting

4 Best Cryptos to Buy Today: Only 1 Stage Left and BTFD’s 12,200+ Bulls Know What’s Coming—BONK and MEW Also on Watch

Bitcoin Surges Past $105,000, Setting Stage for Potential New All-Time High

Buffett Won't Be on Stage for Questions at Berkshire's 2026 Annual Meeting: Report -- Barrons.com

Best Cryptos to Join For Long Term: Troller Cat Jumps 34.95% in Stage 5 as Bonk and Ski Mask Dog Stall

Merck Says Late-Stage Ovarian Cancer Trial for Keytruda Meets Primary Endpoint

MT Newswires Live

Naver D2SF Backs 115 Early-Stage Tech Startups

MT Newswires Live

Revolution Medicines Doses First Patient in Late-Stage Trial Evaluating Daraxonrasib to Treat Lung Cancer

MT Newswires Live

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/SSI/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"SSI","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"SSI\",,,,,undefined,":{"symbol":"SSI","market":"US","secType":"STK","nameCN":"Stage","latestPrice":0.3754,"timestamp":1588968000000,"preClose":0.3754,"halted":3,"volume":0,"delay":0,"floatShares":20307519,"shares":28911336,"eps":-3.332056,"marketStatus":"Halted","change":0,"latestTime":"05-08 16:00:00 EDT","open":0.3754,"high":0.3754,"low":0.3754,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-3.332056,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1748332800000},"marketStatusCode":7,"adr":0,"adrRate":0,"listingDate":998884800000,"exchange":"NYSE","adjPreClose":0.3754,"dividendRate":0.133191,"volumeRatio":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"SSI\",,,,,undefined,":{"symbol":"SSI","floatShares":20307519,"roa":"-3.54%","roe":"-44.60%","lyrEps":-3.1264,"shares":28911336,"dividePrice":0.05,"high":0.3754,"amplitude":0,"preClose":0.3754,"low":0.3754,"week52Low":0.27,"pbRate":"0.07","week52High":9.5,"institutionHeld":0.5253,"latestPrice":0.3754,"eps":-3.332056,"divideRate":0.133191,"volume":0,"delay":0,"ttmEps":-3.332056,"open":0.3754,"prevYearClose":8.12},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"SSI\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2538190684","title":"Stage 6 Now Live: 3 Best Meme Coin Presales to Buy Now Feature Dogecoin, Pepe, and a Low-Cap Gem at $0.00001459","url":"https://stock-news.laohu8.com/highlight/detail?id=2538190684","media":"CoinMarketCap","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2538190684?lang=en_us&edition=fundamental","pubTime":"2025-05-25 06:34","pubTimestamp":1748126063,"startTime":"0","endTime":"0","summary":"Could meme coins be the secret ingredient to the next wave of crypto millionaires?As Bitcoin shoots past $111,861 and major altcoins like Dogecoin, XRP, and Solana ignite a fresh rally, meme coins are once again dominating conversation. Not just for fun anymore, these digital assets have evolved into full-scale economic microcosms, where staking, deflation, and utility drive serious potential. This is no longer just a game of memes—it's a gateway to generational wealth.Leading this surge is Troller Cat , a presale phenomenon rewriting the meme coin playbook. With a live presale that’s rapidly gaining momentum, $TCAT introduces a layered model featuring high-yield staking, a deflationary P2E game economy, and aggressive ROI projections. Alongside classics like Dogecoin and emerging stars like Pepe, Troller Cat is drawing global attention for its tokenomics and transparency. Those looking to buy TCAT early are locking in steep discounts before the next price increase. Timing is everythin","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://coinmarketcap.com/community/articles/683249719be12759f5c8ac31/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"coinmarketcap_highlight","symbols":["SSI","DOGE.USD.HKCC"],"gpt_icon":0},{"id":"2537958121","title":"Missed Dogs? This Cat’s Stage 5 Is Ending—4453.17% ROI Still on the Table","url":"https://stock-news.laohu8.com/highlight/detail?id=2537958121","media":"CoinMarketCap","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2537958121?lang=en_us&edition=fundamental","pubTime":"2025-05-24 18:49","pubTimestamp":1748083788,"startTime":"0","endTime":"0","summary":"What if the next 100x meme coin isn’t barking—but purring?The meme coin world is heating up again, thanks to Bitcoin smashing a new all-time high above $111,800. Altcoins like XRP, Solana, and Dogecoin have been clawing back into the spotlight, setting off a wave of excitement across crypto communities. With so many traders bagging solid gains from low-cap tokens, meme coin mania is officially back. Projects like Dogs for Scale have rewarded early believers, and investors wonder what’s next.Enter Troller Cat—a meme coin with serious claws. While many are just waking up to its cosmic trolling narrative, those already plugged into this presale are locking in significant numbers. The Troller Cat presale is gaining steam, with Stage 5 ending just 48 hours before a 25.04% price hike. Buy TCAT today at $0.00001166 and you’re still ahead of the curve, with a potential 4453.17% ROI from listing. With over $150,000 raised and rumors swirling about high-stakes rewards and a deflationary game cen","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://coinmarketcap.com/community/articles/6831a44e8baecf490987d664/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"coinmarketcap_highlight","symbols":["SSI"],"gpt_icon":0},{"id":"2537857155","title":"Market Chatter: Nippon Steel President Says Talks With US Government Over US Steel Takeover at Final Stage","url":"https://stock-news.laohu8.com/highlight/detail?id=2537857155","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2537857155?lang=en_us&edition=fundamental","pubTime":"2025-05-24 00:15","pubTimestamp":1748016901,"startTime":"0","endTime":"0","summary":"Nippon Steel's talks with the US government over its planned acquisition of US Steel  are in the final stage, Nikkei Asia reported Friday, citing Nippon Steel President Tadashi Imai.Imai said that they are now waiting for US President Donald Trump's final decision on the deal, according to the report.He expressed hope that US authorities will recognize the potential benefits of Nippon Steel's investment and technology for US Steel's long-term growth, Nikkei Asia reported.The Committee on Foreign Investment in the United States has submitted its findings to Trump, who must now decide whether to approve the deal, Reuters recently said.Shares of US Steel were up about 6.9% in recent trading.Nippon Steel, US Steel, CFIUS and the US Treasury department did not immediately respond to requests for a comment from MT Newswires.Price: 45.85, Change: +2.95, Percent Change: +6.86","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"8dd6cc10491f0b6c62af30bbc028465b","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4516","BK4006","SSI","BK4588","X","BK4520","BK4585"],"gpt_icon":0},{"id":"2537946220","title":"Press Release: DSS, Inc. Reports Strong Q1 2025 Financial Performance, Setting the Stage for Strategic Growth","url":"https://stock-news.laohu8.com/highlight/detail?id=2537946220","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2537946220?lang=en_us&edition=fundamental","pubTime":"2025-05-22 20:31","pubTimestamp":1747917060,"startTime":"0","endTime":"0","summary":"NEW YORK, May 22, 2025  -- DSS, Inc. , a multinational company operating across diverse industries including packaging, real estate, and biomedical innovation, today announced financial results for the first quarter of 2025, highlighting meaningful progress in its financial repositioning and a strong foundation for corporate execution in the coming quarters.In a quarter focused on streamlining operations and financial discipline, DSS delivered significant improvements in key financial metrics:. -- 28% Year-Over-Year Revenue Growth: Total revenues rose sharply, fueled by. a 30% increase in printed product sales and a nearly doubling of rental. income from the company's real estate segment, which grew from $400,000. -- Strategic Asset Monetization: The Company completed the sale of its Plano,-- Debt Reduction and Capital Discipline: DSS used proceeds from asset sales. BioMedical, DSS raised $1.5 million in new equity capital during Q1.The foregoing material may contain \"forward-looking s","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4087","BK4563","SSI","DSS"],"gpt_icon":0},{"id":"2537945754","title":"Instil Bio, ImmuneOnco Say Lung Cancer Drug `2510 Mid-Stage Trial Enrollment in China on Track for Q3","url":"https://stock-news.laohu8.com/highlight/detail?id=2537945754","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2537945754?lang=en_us&edition=fundamental","pubTime":"2025-05-22 20:03","pubTimestamp":1747915391,"startTime":"0","endTime":"0","summary":"Instil Bio  and ImmuneOnco Biopharmaceuticals said Thursday that they expect to complete enrollment in the mid-stage trial of their non-small cell lung cancer drug IMM2510/AXN-2510, or `2510, for multiple solid tumors in China by Q3.The companies said they expect initial safety and efficacy data from the study, which is testing `2510 in combination with chemotherapy, in H2.The companies said that, in parallel, they plan to begin a US phase 1b/2 trial of `2510 monotherapy in relapsed or refractory solid tumors later this year.A late-stage trial of `2510 in combination with chemotherapy is expected to begin in mid-2026 in China, the companies said.Shares of the company were up over 5.4% in recent Thursday premarket activity.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["TIL","SSI","BK4139","BK4505"],"gpt_icon":0},{"id":"2537583309","title":"Mind Medicine’s Strategic Advancements and Late-Stage Pipeline Progress Justify Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2537583309","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2537583309?lang=en_us&edition=fundamental","pubTime":"2025-05-22 00:45","pubTimestamp":1747845910,"startTime":"0","endTime":"0","summary":"H.C. Wainwright analyst Patrick Trucchio reiterated a Buy rating on Mind Medicine (MNMD – Research Report) today and set a price target of $55.00. ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/mind-medicines-strategic-advancements-and-late-stage-pipeline-progress-justify-buy-rating?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/mind-medicines-strategic-advancements-and-late-stage-pipeline-progress-justify-buy-rating?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SSI","PRGS"],"gpt_icon":0},{"id":"2537983273","title":"Google I/O Conference Takes the Stage: Entering the 'AI Era,' Can Investor Confidence Rebound?","url":"https://stock-news.laohu8.com/highlight/detail?id=2537983273","media":"TradingKey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2537983273?lang=en_us&edition=fundamental","pubTime":"2025-05-21 17:27","pubTimestamp":1747819647,"startTime":"0","endTime":"0","summary":"TradingKey - Google hosted its I/O conference on May 20-21, which was viewed as a \"critical moment\" for the company to bolster its faltering stock price. ","market":"us","thumbnail":"https://resource.tradingkey.com/cms_uploads/img/20240105/3ef2bcdbb4abf1400a8c6073034cea51.jpg","type":0,"news_type":0,"thumbnails":["https://resource.tradingkey.com/cms_uploads/img/20240105/3ef2bcdbb4abf1400a8c6073034cea51.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"690b22e15a191690b01dc6c36f85bbf0","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tradingkey.com/news/stocks/250713408-google-i-o-conference-takes-stage-entering-ai-era-investor-confidence-rebound-tradingkey-jane","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2087625088.SGD","LU0203345920.USD","LU0256863811.USD","LU0079474960.USD","LU0426417589.USD","USJW.SI","LU0211328371.USD","LU1923623000.USD","LU2237443978.SGD","SSI","LU0106261372.USD","LU1633808545.USD","LU0980610538.SGD","LU0861579265.USD","LU2602419157.SGD","GOOG","LU0640476718.USD","IE00BSNM7G36.USD","LU2471134879.HKD","LU2403377893.USD","LU0310800379.SGD","LU1917777945.USD","IE00BZ199S13.USD","LU0345769631.USD","LU0528227936.USD","LU0289941410.SGD","LU2271345857.HKD","BK4579","LU2764263039.SGD","LU0127658192.USD","IE00B4JS1V06.HKD","LU1116320737.USD","GOOGL","LU2430703178.SGD","LU2430703251.USD","LU2720916845.USD","SGXZ99366536.SGD","LU0048573561.USD","LU0072462426.USD","LU0345774391.USD","LU2063271972.USD","LU0154236417.USD","SG9999018857.SGD","LU1551013425.SGD","IE00BJLML261.HKD","BK4534","SG9999014906.USD","LU2168564149.EUR","LU0308772762.SGD","LU0985320562.USD"],"gpt_icon":1},{"id":"2536174836","title":"Zymeworks: Hold Rating Maintained Amid Financial Improvements and Early-Stage Growth Potential","url":"https://stock-news.laohu8.com/highlight/detail?id=2536174836","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2536174836?lang=en_us&edition=fundamental","pubTime":"2025-05-20 20:35","pubTimestamp":1747744520,"startTime":"0","endTime":"0","summary":"Analyst Robert Burns of H.C. Wainwright reiterated a Hold rating on Zymeworks (ZYME – Research Report), retaining the price target of $13.00. Rober...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/zymeworks-hold-rating-maintained-amid-financial-improvements-and-early-stage-growth-potential?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/zymeworks-hold-rating-maintained-amid-financial-improvements-and-early-stage-growth-potential?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SSI"],"gpt_icon":0},{"id":"2536668276","title":"Succinct is set to launch the Succinct Prover Network architecture and the PROVE token.","url":"https://stock-news.laohu8.com/highlight/detail?id=2536668276","media":"Blockbeats","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2536668276?lang=en_us&edition=fundamental","pubTime":"2025-05-20 10:37","pubTimestamp":1747708620,"startTime":"0","endTime":"0","summary":"BlockBeats News, May 20th, Web3 infrastructure company Succinct plans to launch the Succinct Prover Network architecture and the PROVE token. The network coordinates distributed provers to generate proofs for various applications, with PROVE serving as the utility token. The initial token supply is 1 billion, and proof providers are incentivized through staking, governance, and auction mechanisms to offer competitive pricing. The network adopts a vApp architecture, combining off-chain auction services and on-chain settlement contracts to provide a high-performance experience. Additionally, the Stage 2.5 version of the testnet is set to be released soon, supporting end-to-end deployment.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.theblockbeats.info//en/flash/294611","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"theblockbeats_live","symbols":["SSI"],"gpt_icon":0},{"id":"2536543396","title":"UBE Corporation Unveils ‘UBE Vision 2030 Transformation — 2nd Stage’","url":"https://stock-news.laohu8.com/highlight/detail?id=2536543396","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2536543396?lang=en_us&edition=fundamental","pubTime":"2025-05-20 08:52","pubTimestamp":1747702339,"startTime":"0","endTime":"0","summary":"UBE Industries ( ($JP:4208) ) just unveiled an announcement. UBE Corporation has announced its new medium-term management plan, ‘UBE Vision 2030 Tr...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/ube-corporation-unveils-ube-vision-2030-transformation-2nd-stage?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/ube-corporation-unveils-ube-vision-2030-transformation-2nd-stage?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SSI"],"gpt_icon":0},{"id":"2536316506","title":"Astrazeneca's Asthma Therapy Shows Improvement Across Primary and Secondary Endpoints in Late-Stage Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2536316506","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2536316506?lang=en_us&edition=fundamental","pubTime":"2025-05-20 01:20","pubTimestamp":1747675203,"startTime":"0","endTime":"0","summary":"Astrazeneca  said Monday its phase 3b trial of Airsupra asthma rescue therapy showcased statistically meaningful improvements across primary and secondary endpoints in patients with mild asthma compared with albuterol medicine.The primary efficacy endpoint was the time to first severe asthma exacerbation during the trial. Secondary endpoints involved severe exacerbation rate and usage of total systemic corticosteroids. The trial revealed that Airsupra markedly lowered the risk of a severe exacerbation by 47% compared with albuterol, the company said.Regarding secondary endpoints, patients on Airsupra had 63% lower exposure to total systemic corticosteroids during treatment versus albuterol alone, reducing risks from cumulative exposure to SCS. Comparable reductions across primary and secondary endpoints were also observed in a prespecified subgroup of adult patients, according to the company.The trial results show that Airsupra's safety and tolerability were consistent with its safety ","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4588","LU2236285917.USD","AZN","LU2417539215.USD","LU2456880835.USD","SSI","LU0320765992.SGD","BK4568","BK4585","BK4007","LU0109394709.USD","LU1829250122.USD","LU0889565916.HKD","LU2462157665.USD"],"gpt_icon":0},{"id":"2536633767","title":"Warren Buffett Will Not Take Stage at Berkshire Hathaway’s (BRK.B) Future Annual Meetings","url":"https://stock-news.laohu8.com/highlight/detail?id=2536633767","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2536633767?lang=en_us&edition=fundamental","pubTime":"2025-05-19 22:51","pubTimestamp":1747666308,"startTime":"0","endTime":"0","summary":"Shareholders had hoped Buffett would retain a big role at the annual gathering in Omaha.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/warren-buffett-will-not-take-stage-at-berkshire-hathaways-brk-b-future-annual-meetings?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/warren-buffett-will-not-take-stage-at-berkshire-hathaways-brk-b-future-annual-meetings?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4588","BK4550","LU0417517546.SGD","LU1074936037.SGD","LU2168564222.USD","LU2168564065.EUR","LU1201861249.SGD","LU0251131958.USD","BRK.A","IE00BWXC8680.SGD","BK4176","LU0170899867.USD","LU1280957306.USD","LU0130102774.USD","IE00B1XK9C88.USD","LU0742534661.SGD","LU2168563687.JPY","LU0648001328.SGD","LU1363072403.SGD","LU2168564149.EUR","BK4534","IE00B3S45H60.SGD","IE00BK4W5L77.USD","IE000M9KFDE8.USD","IE00B775SV38.USD","LU0234570918.USD","LU0683600562.USD","LU0234572021.USD","IE00BKDWB100.SGD","LU0787776722.HKD","IE00BK4W5M84.HKD","LU1366333091.USD","LU0048573561.USD","BRK.B","LU0053666078.USD","LU0149725797.USD","LU0640476718.USD","LU1914381329.SGD","LU0251142724.SGD","BK4585","LU0157215616.USD","SSI","IE00B1BXHZ80.USD","LU0256863811.USD","LU0980610538.SGD","LU2168564495.EUR","BK4581","IE00BJLML261.HKD","LU0971096721.USD","LU0154236417.USD"],"gpt_icon":0},{"id":"2536363880","title":"Warren Buffett Won't Take the Stage for Questions at Berkshire's Next Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2536363880","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2536363880?lang=en_us&edition=fundamental","pubTime":"2025-05-19 22:12","pubTimestamp":1747663920,"startTime":"0","endTime":"0","summary":"Warren Buffett is handing the big question-and-answer session at Berkshire Hathaway's annual meeting over to his successor as CEO, Greg Abel.Devotees of the legendary investor had relished the yearly chance to hear Buffett weigh in on everything from Berkshire's business to the broader economy to life in general.Buffett surprised the investing world earlier this month when he said at Berkshire's annual meeting that he planned to step down as chief executive at the end of 2025. The company said Buffett will remain chairman of its board of directors.At Berkshire's next annual meeting on May 2, 2026, Buffett will join other directors seated on the Omaha, Neb., arena's floor as Abel fields questions, the Omaha World-Herald reported Sunday. Debbie Bosanek, Buffett's executive assistant, confirmed the change.Susie Buffett, Buffett's daughter and a Berkshire director, told the World-Herald that Abel will handle the question-and-answer session because that is how her father wants it.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"30e5c287077b8334dc72d0fa071a4795","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BRK.A","LU0234570918.USD","LU0157215616.USD","LU1914381329.SGD","SSI","IE00B1BXHZ80.USD","LU1201861249.SGD","LU0683600562.USD","BK4588","BK4534","IE00BK4W5L77.USD","BK4533","LU0170899867.USD","LU0787776722.HKD","IE0034235303.USD","LU0417517546.SGD","LU2168564222.USD","BK4581","LU0640476718.USD","LU0648001328.SGD","LU1280957306.USD","LU0154236417.USD","IE00BK4W5M84.HKD","LU0053666078.USD","LU0234572021.USD","IE000M9KFDE8.USD","LU1571399168.USD","LU2168563687.JPY","BK4550","IE00BJLML261.HKD","IE00B775SV38.USD","LU0251142724.SGD","IE00BWXC8680.SGD","LU0742534661.SGD","LU2168564149.EUR","LU1363072403.SGD","BK4585","LU0971096721.USD","LU0251131958.USD","IE00BKDWB100.SGD","LU0130102774.USD","LU0149725797.USD","LU2168564495.EUR","LU0980610538.SGD","BK4176","LU1366333091.USD","LU0048573561.USD","IE00B1XK9C88.USD","BRK.B","IE00B3S45H60.SGD"],"gpt_icon":1},{"id":"2536162595","title":"4 Best Cryptos to Buy Today: Only 1 Stage Left and BTFD’s 12,200+ Bulls Know What’s Coming—BONK and MEW Also on Watch","url":"https://stock-news.laohu8.com/highlight/detail?id=2536162595","media":"CoinMarketCap","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2536162595?lang=en_us&edition=fundamental","pubTime":"2025-05-19 04:49","pubTimestamp":1747601378,"startTime":"0","endTime":"0","summary":"What if one bold move today could turn your $2K into $18K by next month?Whales are betting big that it can, snagging BTFD Coin  like candy on clearance. With the meme coin market bouncing back fast and crypto degen season in full swing, it’s not just a matter of holding anymore—it’s about getting in early. Everyone wants the next massive 100x move, but few jump before the rocket launches.Here’s the kicker: BTFD Coin is in Stage 15 of its presale, selling at just $0.0002, and it’s almost gone. One more stage left before it explodes onto the exchanges at $0.0006, with whales grabbing billions while others hesitate.This article breaks down the best cryptos to buy today, featuring 4 high-potential coins—but the BTFD presale is the only one still offering triple-digit gains before launch. Let’s break it down.The hype isn’t just for show. BTFD has already raised over $7 million, sold 74B+ tokens, and now boasts 12,200+ holders. What’s fueling the fire?","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://coinmarketcap.com/community/articles/682a47e36c8b356473b35d90/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"coinmarketcap_highlight","symbols":["SSI","SOL.USD.HKCC"],"gpt_icon":0},{"id":"2536590258","title":"Bitcoin Surges Past $105,000, Setting Stage for Potential New All-Time High","url":"https://stock-news.laohu8.com/highlight/detail?id=2536590258","media":"CoinMarketCap","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2536590258?lang=en_us&edition=fundamental","pubTime":"2025-05-19 01:49","pubTimestamp":1747590587,"startTime":"0","endTime":"0","summary":"On May 18, 2025, Bitcoin  surged beyond the $105,000 mark, signaling a robust bullish momentum in the cryptocurrency market. This milestone represents one of the highest weekly closes ever recorded for BTC, fueling optimism among traders and investors about a possible breakthrough to new all-time highs in the near term.Bitcoin’s price climbed to approximately $105,481, reflecting a 2.37% increase within 24 hours and pushing its market capitalization above $2.1 trillion. The cryptocurrency has maintained a strong position above the $100,000 threshold, a level it has held since early May, demonstrating resilience amid market fluctuations.The recent price strength coincides with favorable macroeconomic conditions, including a recovering stock market and increased institutional interest in cryptocurrencies. The S&P 500’s recent gains have contributed to a risk-on sentiment that often benefits digital assets like Bitcoin.In summary, Bitcoin’s breakthrough past $105,000 on May 18, 2025, mark","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://coinmarketcap.com/community/articles/682a1dbfcd499e12314b8b9d/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"coinmarketcap_highlight","symbols":["BK4588","BK4594","BTC.USD.HKCC","BTC","BTC.USD.CC","SSI","BK4601","BK4585"],"gpt_icon":1},{"id":"2536059917","title":"Buffett Won't Be on Stage for Questions at Berkshire's 2026 Annual Meeting: Report -- Barrons.com","url":"https://stock-news.laohu8.com/highlight/detail?id=2536059917","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2536059917?lang=en_us&edition=fundamental","pubTime":"2025-05-18 23:19","pubTimestamp":1747581540,"startTime":"0","endTime":"0","summary":"It looks like it will be Greg Abel's show at Berkshire Hathaway's 2026 annual meeting in Omaha.The Omaha World-Herald reported Sunday that Berkshire CEO Warren Buffett won't be on stage with Berkshire executive Abel to answer shareholder questions. Abel, 62, is set to take over as CEO at the beginning of next year.Buffett will be seated on the floor of the CHI Health Center arena in Omaha along with other Berkshire directors, the newspaper reported. Buffett will remain chairman while giving up the CEO role at the end of 2025. Buffett, 94, has led Berkshire for 60 years.Buffett's daughter Susan, who is a member of the Berkshire board, told the newspaper that her father felt it was appropriate for Abel to be on stage without Warren Buffett given Abel's future role as CEO.One of the first questions at the 2025 meeting, for example, was about a hot-dog business that a shareholder thought Berkshire owned but is actually owned by a private equity firm Berkshire Partners. Then there were ques","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4533","LU0251142724.SGD","LU0640476718.USD","LU0053666078.USD","IE00BK4W5L77.USD","BK4585","LU1280957306.USD","LU2168563687.JPY","IE00BJLML261.HKD","BRK.B","BK4550","BK4176","SSI","IE0034235303.USD","LU0234572021.USD","LU0648001328.SGD","LU0130102774.USD","IE00BKDWB100.SGD","IE00BK4W5M84.HKD","IE00B3S45H60.SGD","LU0154236417.USD","LU0256863811.USD","LU2168564149.EUR","LU1914381329.SGD","LU0683600562.USD","LU2168564495.EUR","LU0048573561.USD","BK4534","LU1571399168.USD","IE00B775SV38.USD","BK4588","LU1366333091.USD","LU0787776722.HKD","LU0251131958.USD","LU0742534661.SGD","LU1074936037.SGD","IE00BWXC8680.SGD","LU0417517546.SGD","LU2168564065.EUR","LU0157215616.USD","LU1363072403.SGD","LU2168564222.USD","IE00B1BXHZ80.USD","LU0234570918.USD","BRK.A","BK4581","IE000M9KFDE8.USD","LU0170899867.USD","LU0149725797.USD","IE00B1XK9C88.USD"],"gpt_icon":1},{"id":"2536323443","title":"Best Cryptos to Join For Long Term: Troller Cat Jumps 34.95% in Stage 5 as Bonk and Ski Mask Dog Stall","url":"https://stock-news.laohu8.com/highlight/detail?id=2536323443","media":"CoinMarketCap","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2536323443?lang=en_us&edition=fundamental","pubTime":"2025-05-17 04:34","pubTimestamp":1747427662,"startTime":"0","endTime":"0","summary":"What happens when meme mania meets real mechanics?While Bonk slips and Ski Mask Dog sprints without substance, Troller Cat has clawed into serious investor conversations. It’s not just vibes and virality anymore. In a crypto cycle where the smartest investors are chasing the best cryptos to join for the long term, the rise of structured, utility-driven meme coins has flipped the script.And let’s talk real-life impact. Imagine a 27-year-old construction worker in Brazil earning $300 a month. If he invests $100 in Stage 5, he could walk away with nearly 8.5 million $TCAT tokens. At launch, that’s worth $4,550+. That’s rent, bills, food, and a savings buffer. Now scale it up: a $1,000 investment means $45,500 at listing, which doesn’t even factor in staking rewards. Trollercat.com is designed to help everyda","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://coinmarketcap.com/community/articles/6827a150b3d95572ab5f09cd/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"coinmarketcap_highlight","symbols":["TON.USD.CC","APT.USD.HKCC","SSI","APT.USD.CC","TON.USD.HKCC"],"gpt_icon":0},{"id":"2535460768","title":"Merck Says Late-Stage Ovarian Cancer Trial for Keytruda Meets Primary Endpoint","url":"https://stock-news.laohu8.com/highlight/detail?id=2535460768","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535460768?lang=en_us&edition=fundamental","pubTime":"2025-05-15 19:22","pubTimestamp":1747308130,"startTime":"0","endTime":"0","summary":"Merck  said Thursday its late-stage trial evaluating its cancer drug Keytruda in combination with chemotherapy with or without bevacizumab met its primary endpoint of progression-free survival in patients with platinum-resistant recurrent ovarian cancer whose tumors expressed PD-L1 and in all comers.The trial also met a secondary endpoint of overall survival in patients whose tumors express PD-L1, the company said.The trial showed no new safety signals for Keytruda as the safety profile remained consistent with that observed in previously reported studies.Merck said the study is continuing and that the final overall survival results for the entire study population will be evaluated at a future analysis.The company's shares were up about 1% in recent premarket activity on Thursday.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU1934455277.USD","LU1929549753.HKD","SG9999014542.SGD","LU1571399168.USD","LU0058720904.USD","LU0861579265.USD","IE00BFTCPJ56.SGD","IE0002141913.USD","SG9999001176.SGD","LU1989771016.USD","SG9999002224.SGD","LU1585245621.USD","SG9999001176.USD","IE00BJJMRZ35.SGD","LU2089984988.USD","BK4588","LU2361044865.SGD","LU1037948541.HKD","BK4559","LU0208291251.USD","LU1116320901.HKD","SGXZ57979304.SGD","LU1162221912.USD","LU2361045086.USD","MRK","LU1934455863.HKD","BK4533","LU1066051811.HKD","LU1093756325.SGD","LU1430594728.SGD","SG9999014567.USD","LU2361044949.HKD","SG9999002232.USD","LU0006306889.USD","LU0211331839.USD","LU0965509101.SGD","LU1057294990.SGD","IE0009355771.USD","LU0265550359.USD","SSI","SG9999001440.SGD","IE00BJT1NW94.SGD","LU1116320737.USD","LU0238689110.USD","LU0320765646.SGD","LU2461242641.AUD","IE00B4R5TH58.HKD","BK4516","IE00BSNM7G36.USD","LU1941712264.USD"],"gpt_icon":1},{"id":"2535856249","title":"Naver D2SF Backs 115 Early-Stage Tech Startups","url":"https://stock-news.laohu8.com/highlight/detail?id=2535856249","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535856249?lang=en_us&edition=fundamental","pubTime":"2025-05-15 11:35","pubTimestamp":1747280119,"startTime":"0","endTime":"0","summary":"Naver's  corporate venture capital arm D2SF invested in 115 seed and Series A tech startups over the past decade, achieving a 96% survival rate and a cumulative corporate value of 5.2 trillion won, Naver said in a Tuesday release.About 64% of portfolio firms have launched collaborative initiatives with Naver. D2SF plans to continue nurturing South Korea's technology ecosystem and supporting global expansion through investments, value-up programs, and student startup competitions, the release said.Shares of Naver fell 1% in recent trade.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["SSI"],"gpt_icon":0},{"id":"2535240570","title":"Revolution Medicines Doses First Patient in Late-Stage Trial Evaluating Daraxonrasib to Treat Lung Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2535240570","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535240570?lang=en_us&edition=fundamental","pubTime":"2025-05-14 21:08","pubTimestamp":1747228128,"startTime":"0","endTime":"0","summary":"Revolution Medicines  said Wednesday the first patient has been dosed in a phase 3 trial evaluating daraxonrasib in patients with previously treated, locally advanced or metastatic RAS mutant non-small cell lung cancer compared to docetaxel chemotherapy.The trial is expected to enroll around 420 patients, with dual primary endpoints of progression-free survival and overall survival, the company said.The decision to evaluate daraxonrasib as a monotherapy was informed by early evidence from a single-arm trial showing that the compound had an acceptable safety profile and encouraging antitumor activity, the company said.Revolution Medicines' shares rose by more than 2% in premarket trading.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["SSI","MDCO","BK4139","RVMD"],"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":1,"totalSize":200,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/SSI\",params:#limit:5,,,undefined,":[{"market":"US","date":"2019-11-21","symbol":"SSI","fiscalQuarterEnding":"2019/10","expectedEps":null,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1574312400000,"reportTimeType":"pre","actualEps":-0.15},{"date":"2019-08-22","symbol":"SSI","type":"earning","reportTimeType":"pre","market":"US","fiscalQuarterEnding":"2019/07","expectedEps":null,"defaultRemindTime":1566460800000,"name":null,"time":"Pre-Market","dateTimestamp":1566446400000,"actualEps":-0.6},{"market":"US","date":"2019-05-23","symbol":"SSI","fiscalQuarterEnding":"2019/04","expectedEps":null,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1558584000000,"reportTimeType":"pre","actualEps":-1.67},{"market":"US","date":"2019-03-07","symbol":"SSI","fiscalQuarterEnding":"2019/01","expectedEps":0.73,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1551934800000,"reportTimeType":"pre","actualEps":0.25},{"market":"US","date":"2018-12-03","symbol":"SSI","amount":0.05,"name":"Stage Stores Inc","currency":"USD","type":"dividend","dateTimestamp":1543813200000}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"SSI\",market:\"US\",,,undefined,":[{"executeDate":"2017-02-24","recordDate":null,"paymentDate":null,"value":0.15,"currency":"USD"},{"executeDate":"2017-05-25","recordDate":null,"paymentDate":null,"value":0.05,"currency":"USD"},{"executeDate":"2017-08-25","recordDate":null,"paymentDate":null,"value":0.05,"currency":"USD"},{"executeDate":"2017-11-27","recordDate":null,"paymentDate":null,"value":0.05,"currency":"USD"},{"executeDate":"2018-03-05","recordDate":null,"paymentDate":null,"value":0.05,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"SSI\",market:\"US\",delay:false,,,undefined,":{}}}